Ischemic heart disease (IHD) confers signifi cant morbidity and mortality despite advances in medical therapy and percutaneous and surgical revascularization. Based on unmet clinical need, the development of new treatment strategies, such as cell delivery, has progres sively grown in momentum over the past decade. To date, many cell types have been applied experimentally for their potential reparative cardiac benefi ts. As challenges have become apparent for each cell candidate, preclinical investigators have set about tackling them with great vigor, pushing forward at a rapid rate with the optimization of newer-generation cell products and delivery techniques. Although the merits of translation to clinical practice have been debated on grounds of insuffi cient mechanistic data, uncertainty about cell biology and suboptimal engraftment and regenerative potential, this has not deterred evaluation of cell therapy in patients from continuing at a global level.
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Initially conceived as a regenerative strategy to address the loss of cardiomyocytes after myocardial injury, most clinical studies have investigated the delivery of cells to aff ect ventricular remodeling after myocardial infarction (MI). Although diff erent trials have shown confl icting outcomes, summarized data have concluded that cell therapy has a good safety record after MI, with overall modest benefi ts on surrogate endpoints, including ejection fraction and infarct size [1] . By comparison with MI, other cardiovascular patient groups with similar scope for benefi t from cell delivery have not been investigated as aggressively.
Against this backdrop, the recently published, multicenter, phase II ACT34-CMI trial [2] represents a novel and worthwhile contribution to the body of human cell therapy experience. On the basis of preclinical observations and encouraging fi ndings from an earlier phase I/ IIa study [3] , Losordo and colleagues hypothesized that catheter-based injection of blood-derived CD34 + progenitor cells into regions of ischemic myocardium would result in improvement in angina frequency and exercise tolerance in patients with class III and IV chronic refractory angina. Th ey randomized 167 subjects to receive either low-dose (1 x 10 5 cells/kg) or high-dose (5 x 10 5 /kg) CD34 + cells after mobilization with granulocyte colonystimulating factor or placebo. Th ese patients constituted an at-need cohort, with frequent symptoms of IHD despite maximal anti-anginal pharmacotherapy, and had exhausted therapeutic options for percutaneous or surgical revascularization. As such, they represented an
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ideal target for treatment with an experimental agent due to their favorable risk-benefi t ratio. In addition, as highlighted by the investigators, the problem of refractory angina is of considerable magnitude to society, aff ecting up to 850,000 people per year in the United States, although population-based estimates may vary [4] . Enrollment of these patients into clinical trials can be challenging and previous studies of cell therapy for chronic IHD have comprised smaller sample sizes [3, 5, 6] .
Th e choice of CD34 + progenitor cells to reduce myocardial ischemic burden has a solid preclinical rationale and refl ects an important advance from the status quo of human studies, which have mostly used the total cell content or mononuclear cell fraction of bone marrow (BM) aspirates [7] . Although easy to isolate, unselected BM cell preparations are heterogeneous and contain a very low percentage of immature progenitor or stem cells. In theory, this may limit their therapeutic capacity and better outcomes might be intuitively expected by implementing more enriched progenitor cell populations. Since their original description, our understanding of the biological nature of CD34 + cells has taken a circuitous course, from the initial notion that these were endothelial progenitor cells to increasing recognition of their hemato poietic lineage [8] . Irrespective, these cells are well known to have striking provasculogenic properties, mediated in large part through paracrine mechanisms. In animal models of myocardial ischemia, their transplantation has resulted in favorable eff ects on myocardial capillary density, perfusion, collagen deposition and contractile function that have been shown to exceed those obtained from unfractionated BM cells [9] .
Importantly, the ACT34-CMI trial has confi rmed that these mechanistic eff ects extend to improvement in clinical endpoints in patients with chronic IHD. By comparison with placebo, recipients of a low cell dose exhibited a strong reduction in weekly angina frequency and a doubling of exercise tolerance time at 6 and 12 months of follow-up. Th is was accompanied by trends favoring cell therapy in angina class, symptom questionnaire responses and use of sublingual nitroglycerines, along with nonsignifi cant decreases in mortality and major cardiovascular event rates. Interestingly, all positive outcomes were more modest and not statistically defi nitive in patients who received a high cell dose. Myocardial perfusion imaging with single-photon emission computed tomography also revealed an improvement in total severity score in the low-dose group compared with placebo, although diff erences were not found for other perfusion parameters. Th e authors rationalized that CD34 + cell delivery may have mediated symptomatic benefi t by imparting microvascular changes that might not be detectable by conventional single-photon emission computed tomography imaging. Overall, the safety profi le of cell treatment was also acceptable. Not surprisingly, administration of granulocyte colony-stimulating factor was found to exacerbate angina episodes and to induce mild cardiac biomarker release, while there were two cases of myocardial perforation caused by intramyocardial cell injection.
One of the acknowledged limitations of early cell therapy studies was that their nonrandomized design and use of surrogate endpoints may have resulted in overinterpretation of therapeutic results. In this regard, the ACT34-CMI trial is meritorious in primarily focusing on parameters that are of immediate clinical relevance, using measurements that are robust and rigorous. Th e persistence of symptomatic improvement at 12-month followup in the low-dose group is especially reassuring, as previous data have suggested that the incremental benefi t from BM cell therapy for MI may only be transient.
Although not powered to specifi cally compare outcomes between low-dose and high-dose cell therapy, the ACT34-CMI trial also highlights that the cell dose is a determinant of therapeutic response, but not necessarily in the intuitive sense that more cells equate to a larger eff ect. Th is is consistent with animal data show ing that cells have an optimal ceiling dose, above which engraftment and functional biology may be compromised due to depletion of nutritional resources in the substrate myocardium [10] .
In the setting of autologous BM cell therapy for MI, it is now understood that technical inconsistencies in cell preparation may have contributed to the discrepant outcomes between diff erent studies. It is therefore highly encouraging for large-scale clinical application that the ACT34-CMI investigators were able to successfully coordinate and execute a multistep process for CD34 + mobilization, collection, enrichment and lot testing locally, at each of 26 study sites. Furthermore, individual centers were also responsible for administering cells by percutaneous, catheter-based intramyocardial injection, under the guidance of NOGA® XP electromechanical navigation (Biologics Delivery Systems Group, Cordis Corporation, Diamond Bar, CA, USA), which requires specialized training and a level of technical expertise beyond traditional injection of cells down the coronary arterial tree.
As cardiovascular regenerative medicine rides the wave of ongoing developments in cell and tissue engineering and the promise of impending results from current and future clinical trials, the ACT34-CMI trial provides a timely template for the study of patients with chronic IHD. With sound evidence for feasibility, safety and bioactivity, a phase III study of enriched, CD34 + proangiogenic cells now appears ready for commencement. Although skeptics may advocate deferral pending further preclinical evaluation, the rigorous execution of carefully designed human studies with meaningful endpoints should help focus and complement the questions asked by basic science and provide crucial momentum to keep this exciting fi eld of research moving closer to clinical reality.
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